Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$772.14 - $960.02 $4.86 Million - $6.05 Million
6,300 Added 262.5%
8,700 $7.71 Million
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $144,974 - $181,808
200 Added 9.09%
2,400 $2.17 Million
Q1 2024

May 13, 2024

SELL
$592.2 - $792.28 $4.68 Million - $6.26 Million
-7,900 Reduced 78.22%
2,200 $1.71 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $3.73 Million - $4.4 Million
7,100 Added 236.67%
10,100 $5.89 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $1.3 Million - $1.8 Million
3,000 New
3,000 $1.61 Million
Q2 2022

Aug 15, 2022

BUY
$278.73 - $327.27 $151 Million - $177 Million
541,500 Added 5415.0%
551,500 $179 Million
Q3 2021

Nov 15, 2021

BUY
$221.6 - $272.71 $1.44 Million - $1.77 Million
6,500 Added 185.71%
10,000 $2.31 Million
Q2 2021

Aug 16, 2021

BUY
$180.55 - $233.54 $631,925 - $817,390
3,500 New
3,500 $803,000
Q1 2021

May 17, 2021

SELL
$164.32 - $212.72 $91.6 Million - $119 Million
-557,500 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $68.8 Million - $91.1 Million
527,500 Added 1758.33%
557,500 $94.1 Million
Q3 2020

Nov 16, 2020

SELL
$146.22 - $169.13 $10.2 Million - $11.8 Million
-70,000 Reduced 70.0%
30,000 $4.44 Million
Q2 2020

Aug 14, 2020

BUY
$136.42 - $164.18 $13.6 Million - $16.4 Million
100,000 New
100,000 $16.4 Million
Q1 2020

May 15, 2020

SELL
$119.05 - $147.35 $5.95 Million - $7.37 Million
-50,000 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$106.92 - $132.43 $17.6 Million - $21.9 Million
-165,000 Reduced 76.74%
50,000 $6.57 Million
Q2 2018

Aug 14, 2018

SELL
$75.7 - $86.88 $9.27 Million - $10.6 Million
-122,500 Reduced 36.3%
215,000 $18.3 Million
Q1 2018

May 15, 2018

BUY
$74.21 - $87.6 $25 Million - $29.6 Million
337,500 New
337,500 $26.1 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.